April 2025
1. PANG Y, Li H, Chen X, Cao Y, et al
   A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects.
   Antimicrob Agents Chemother. 2025;69:e0172924.
   

   >> Share

   
   March 2025
2. ZHAO L, Li C, Wang M, Zhou M, et al
   Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier.
   Antimicrob Agents Chemother. 2025 Mar 10:e0155624. doi: 10.1128/aac.01556.
   

   >> Share

   
   February 2025
3. RODRIGUEZ L, Lee HW, Li J, Martin R, et al
   SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.
   Antimicrob Agents Chemother. 2025;69:e0123824.
   

   >> Share

   
   December 2024
4. MENDES S, Guimaraes LC, Costa PAC, Fernandez CC, et al
   Intranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice.
   Antimicrob Agents Chemother. 2024;68:e0083524.
   

   >> Share

   
   November 2024
5. ZHANG M, Lian X, Gao Y, Jiang L, et al
   LDC000067, a CDK9 inhibitor, unveils promising results in suppressing influenza virus infections in vitro and in vivo.
   Antimicrob Agents Chemother. 2024 Nov 20:e0117224. doi: 10.1128/aac.01172.
   

   >> Share

   
   October 2024
6. CARLIN AF, Beadle JR, Ardanuy J, Clark AE, et al
   Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice.
   Antimicrob Agents Chemother. 2024;68:e0103924.
   

   >> Share

   
   
7. MIYASHITA N, Nakamori Y, Ogata M, Fukuda N, et al
   Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers.
   Antimicrob Agents Chemother. 2024;68:e0106424.
   

   >> Share

   
   September 2024
8. FAGHIHI I, Yan VC
   Clinical pharmacodynamics of obeldesivir versus remdesivir.
   Antimicrob Agents Chemother. 2024;68:e0096924.
   

   >> Share

   
   
9. POLI ANR, Tietjen I, Nandwana NK, Cassel J, et al
   Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
   Antimicrob Agents Chemother. 2024 Sep 3:e0056224. doi: 10.1128/aac.00562.
   

   >> Share

   
   August 2024
10. FAGHIHI I, Yan VC
    Remdesivir treatment does not reduce viral titers in patients with COVID-19.
    Antimicrob Agents Chemother. 2024;68:e0085624.
    

    >> Share

    
    
11. SALOMEZ-IHL C, Giai J, Barbado M, Paris A, et al
    H(2) inhalation therapy in patients with moderate COVID-19 (H(2)COVID): a prospective ascending-dose phase I clinical trial.
    Antimicrob Agents Chemother. 2024;68:e0057324.
    

    >> Share

    
    June 2024
12. SHIN JS, Jang Y, Kim D-S, Jung E, et al
    Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate.
    Antimicrob Agents Chemother. 2024;68:e0034124.
    

    >> Share

    
    May 2024
13. CLEGG LE, Stepanov O, Schmidt H, Tang W, et al
    Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
    Antimicrob Agents Chemother. 2024;68:e0158723.
    

    >> Share

    
    April 2024
14. CHESNOKOV A, Ivashchenko AA, Matsuzaki Y, Takashita E, et al
    Influenza C virus susceptibility to antivirals with different mechanisms of action.
    Antimicrob Agents Chemother. 2024 Apr 8:e0172723. doi: 10.1128/aac.01727.
    

    >> Share

    
    
15. XU S, Esmaeili S, Cardozo-Ojeda EF, Goyal A, et al
    Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents.
    Antimicrob Agents Chemother. 2024;68:e0101523.
    

    >> Share

    
    
16. TANG W-F, Chang Y-H, Lin C-C, Jheng J-R, et al
    BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
    Antimicrob Agents Chemother. 2024;68:e0095623.
    

    >> Share

    
    March 2024
17. YU Y, Chen S, Zhang H, Duan Y, et al
    A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection.
    Antimicrob Agents Chemother. 2024 Mar 12:e0135023. doi: 10.1128/aac.01350.
    

    >> Share

    
    
18. MIAH M, Davis AM, Hannoun C, Said JS, et al
    Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus.
    Antimicrob Agents Chemother. 2024;68:e0106423.
    

    >> Share

    
    
19. ZHANG R, Zhou J, Yan H, Liu X, et al
    Manidipine is not a potential inhibitor against SARS-CoV-2 main protease.
    Antimicrob Agents Chemother. 2024;68:e0129723.
    

    >> Share

    
    February 2024
20. PLOTNIK D, Sager JE, Aryal M, Fanget MC, et al
    A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
    Antimicrob Agents Chemother. 2024 Feb 20:e0127323. doi: 10.1128/aac.01273.
    

    >> Share

    
    January 2024
21. YANG H, Yu X, Hou W, Liu X, et al
    Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
    Antimicrob Agents Chemother. 2024 Jan 30:e0138423. doi: 10.1128/aac.01384.
    

    >> Share

    
    
22. BAKER J, Ombredane H, Daly L, Knowles I, et al
    Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice.
    Antimicrob Agents Chemother. 2024;68:e0105023.
    

    >> Share

    
    
23. STRIZKI JM, Gaspar JM, Howe JA, Hutchins B, et al
    Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Antimicrob Agents Chemother. 2024;68:e0095323.
    

    >> Share

    
    December 2023
24. ZHANG H, Zhou J, Chen H, Mao J, et al
    Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171.
    Antimicrob Agents Chemother. 2023 Dec 15:e0111523. doi: 10.1128/aac.01115.
    

    >> Share

    
    November 2023
25. TONG X, Keung W, Arnold LD, Stevens LJ, et al
    Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
    Antimicrob Agents Chemother. 2023;67:e0084023.
    

    >> Share

    
    July 2023
26. PALOMINO-CABRERA R, Tejerina F, Molero-Salinas A, Ferris M, et al
    Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.
    Antimicrob Agents Chemother. 2023;67:e0026623.
    

    >> Share

    
    April 2023
27. DE LEON P, Canas-Arranz R, Bustos MJ, Saiz M, et al
    Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.
    Antimicrob Agents Chemother. 2023;67:e0170322.
    

    >> Share

    
    March 2023
28. ZHANG D, Zhao Y, You X, He S, et al
    Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection.
    Antimicrob Agents Chemother. 2023;67:e0148722.
    

    >> Share

    
    
29. LIU STH, Mirceta M, Lin G, Anderson DM, et al
    Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study.
    Antimicrob Agents Chemother. 2023;67:e0151422.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share